ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

16.09

-0.37 (-2.25%)

At close: Oct 13, 2026, 4:00 PM EDT

16.37

+0.28 (1.74%)

After-hours: Oct 13, 2026, 7:40 PM EDT

ArriVent BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	154.68	45.54	74.29	150.39	163.37	37.28
Short-Term Investments	218.44	267.28	144.57	-	-	-
Cash & Short-Term Investments	373.12	312.82	218.86	150.39	163.37	37.28
Cash Growth	58.31%	42.93%	45.53%	-7.95%	338.23%	-
Other Receivables	-	-	0.5	0.76	0.5	0.25
Receivables	-	-	0.5	0.76	0.5	0.25
Prepaid Expenses	1.15	0.19	0.41	0.37	0.33	0.03
Other Current Assets	19.91	19.89	7.21	8.45	18.42	5.39
Total Current Assets	394.17	332.9	226.98	159.97	182.62	42.95
Property, Plant & Equipment	0.37	0.01	0.15	0.29	0.14	-
Long-Term Investments	-	-	47.68	-	-	-
Long-Term Deferred Charges	0.04	0.07	-	2.73	-	-
Other Long-Term Assets	0.13	0.19	0.13	0.11	0.07	0.09
Total Assets	394.72	333.17	274.94	163.1	182.83	43.04

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2.22	5.93	3.78	4.53	3.09	0.29
Accrued Expenses	25.31	20	13.33	6.95	5.14	1.53
Current Portion of Leases	0.32	0.01	0.16	0.14	0.13	-
Total Current Liabilities	27.84	25.95	17.27	11.62	8.36	1.82
Long-Term Leases	0.03	-	0.01	0.18	0.01	-
Total Liabilities	27.88	25.95	17.29	11.8	8.37	1.82

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0	0	-	-	-
Additional Paid-In Capital	864.96	711.85	496.2	4.65	3.4	2.96
Retained Earnings	-497.85	-404.64	-238.33	-157.85	-88.51	-51.61
Comprehensive Income & Other	-0.27	0.01	-0.21	-	-	-0
Total Common Equity	366.84	307.22	257.65	-153.19	-85.11	-48.64
Shareholders' Equity	366.84	307.22	257.65	151.3	174.46	41.22
Total Liabilities & Equity	394.72	333.17	274.94	163.1	182.83	43.04

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	0.35	0.01	0.18	0.32	0.14	-
Net Cash (Debt)	372.77	312.81	218.69	150.07	163.23	37.28
Net Cash Growth	58.23%	43.04%	45.72%	-8.06%	337.86%	-
Net Cash Per Share	8.39	8.13	6.95	70.10	127.82	52.42
Filing Date Shares Outstanding	49.31	44.2	34.02	33.49	31.96	0.71
Total Common Shares Outstanding	48.32	42.45	33.71	2.75	2.6	0.71
Working Capital	366.33	306.95	209.71	148.34	174.26	41.13
Book Value Per Share	7.59	7.24	7.64	-55.80	-32.76	-68.40
Tangible Book Value	366.84	307.22	257.65	-153.19	-85.11	-48.64
Tangible Book Value Per Share	7.59	7.24	7.64	-55.80	-32.76	-68.40

SEC Filings: 10-K · 10-Q